Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.
Category: Publicity
Life Sciences Report (5-12-15)
An immunotherapy revolution is rocking biotechnology, and investors are searching for just the right way to play the new trend. Do you go with an unknown company where the upside could be unparalleled? Do you go with an older name that has established partnerships with major pharmas? John McCamant, editor of the Medical Technology Stock Letter, has performed some serious diligence, and tells The Life Sciences Report about a handful of names with a range of market caps and the potential to achieve significant investment upside.
Wide World of Stocks (3-16-15)
John McCamant speaks with Damon Roberts, host of Wide World of Stocks “Sector Spotlight” about hot stock picks in the biotech sector. Wide World of Stocks (3-16-15)
The Money Show (2-25-15)
February 25, 2015 Precision Medicine Boost Cancer Research By John McCamant John McCamant:  Sangamo (SGMO) is clearly a second generation gene therapy technology.  They can do a couple of different things than the first generation, but their technology is specifically it’s a rifled approach. They can get right into the specific point within the genome[…]
MarketWatch (5-13-15)
Biotech buyout fever is going to continue. But be careful: You need to pick the right companies and hold them for years. Find out the reasons biotech buyouts will continue and stock picks from biotech analysts including John McCamant of BioInvest.
Wide World of Stocks (4-9-15)
Guest John McCamant, editor of the Medical Technology Stock Letter (MTSL), joins Wide World of Stocks host Damon Roberts to discuss a potential biotech bubble, merger mania, and opportunity with ZIOPHARM (NASDAQ: ZIOP)
MarketWatch (2-26-15)
Beware of biotech stocks. I’m not the only one who is skeptical of the latest monster move in biotech. “At current levels, we believe another pullback is due,” biotechnology expert John McCamant wrote in the most recent edition of his Medical Technology Stock Letter.
MoneyShow Five Prime (1-19-15)
January 19, 2015 FIVE PRIME Written By John McCamant Our top speculative idea for 2015 a classic early-stage platform; the company is a leader in the discovery of innovative protein therapeutics, explains John McCamant, editor of The Medical Technology Stock Letter. Five Prime (FPRX) has built an extremely impressive library comprised of more than 5,600[…]
Forbes (5-13-15)
Gene Marcial of Forbes interviews John McCamant of the Medical Technology Stock Letter to discuss an attractive M&A play in the Biotech Space.
MoneyShow: A Trio of Biotech Favorites (4-6-15)
Our guest today is Jay Silverman, a leading biotechnology sector analyst and editor of The Medical Technology Stock Letter. He updates us on the acquisition of one of his long-standing recommendations, the impact of this deal on the biotech space, and a trio of additional ideas for long-term investors to consider.
Forbes (2-25-15)
February 25, 2015 Is A Renaissance In Surging Biotechs Underway? By Gene Marciel Not too long ago, investing in biotechnology was perceived as plain gambling. The rewards could be high, to be sure, but so were the risks in playing the arcane biotech stocks. That was because a biotech company’s success depended on the development of[…]
Life Sciences Report (12-30-14)
December 30, 2014 Will Biotech Fire on All Cylinders in 2015? Making predictions for the New Year may feel as productive as peering into a crystal ball. But in the life sciences, hard science and long experience back prognostication. The biotech market enjoyed a stellar 2013 and withstood a solid check in early 2014 before[…]